Literature DB >> 25724034

Bethesda System reporting rates for conventional Papanicolaou tests and liquid-based cytology in a large Chinese, College of American Pathologists-certified independent medical laboratory: analysis of 1394389 Papanicolaou test reports.

Baowen Zheng1, R Marshall Austin, Xiaoman Liang, Zaibo Li, Congde Chen, Shanshan Yan, Chengquan Zhao.   

Abstract

CONTEXT: Reports that use the Bethesda System categories for Chinese Papanicolaou test results are rare.
OBJECTIVE: To document and analyze rates reported in the Bethesda System for conventional Papanicolaou tests and liquid-based cytology between 2007 and 2012 in China's largest College of American Pathologists-accredited laboratory.
DESIGN: Results from 1,394,389 Papanicolaou tests, rendered between 2007 and 2012 by the Guangzhou Kingmed Diagnostics Cytology Laboratory, were documented by the Bethesda System report categories and Papanicolaou test methodology, which included both conventional Papanicolaou tests and 4 different liquid-based cytology preparations.
RESULTS: Results were documented for 326,297 conventional Papanicolaou tests and 1,068,092 liquid-based cytology specimens, which included 928,884 ThinPrep (Hologic, Bedford, Massachusetts), 63,465 SurePath (BD Diagnostics, Franklin Lakes, New Jersey), 50,422 Liqui-Prep (LGM International, Melbourne, Florida), and 25,321 Lituo liquid-cytology (Lituo Biotechnology Co, Hunan, China) specimens. Abnormality rates reported were significantly higher with liquid-based cytology than they were with conventional Papanicolaou tests in all the Bethesda System categories (P < .001). Reporting rates were within the 2006 benchmark ranges from the College of American Pathologists, except for atypical glandular cells (low) and unsatisfactory rates for conventional Papanicolaou tests (low).
CONCLUSION: Participation in the international College of American Pathologists Laboratory Accreditation Program provides laboratory quality standards not otherwise available in many international settings.

Mesh:

Year:  2015        PMID: 25724034     DOI: 10.5858/arpa.2014-0070-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil.

Authors:  Philip E Castle; Vânia R S Silva; Marcia E L Consolaro; Nádia Kienen; Lorna Bittencourt; Sandra M Pelloso; Edward E Partridge; Amanda Pierz; Camila B Dartibale; Nelson S Uchimura; Isabel C Scarinci
Journal:  Cancer Prev Res (Phila)       Date:  2019-01-16

2.  Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory.

Authors:  Zhengyu Zeng; Huaitao Yang; Zaibo Li; Xuekui He; Christopher C Griffith; Xiamen Chen; Xiaolei Guo; Baowen Zheng; Shangwei Wu; Chengquan Zhao
Journal:  J Cancer       Date:  2016-05-25       Impact factor: 4.207

3.  Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China.

Authors:  Liran Zhang; Fengxiang Xie; Xinguo Wang; Dezhi Peng; Chunrui Bi; Lingbo Jiang; Dongman Zhao; Xinxin Tian; Debo Qi
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

4.  Risk factors for cervical intraepithelial neoplasia and cervical cancer in Chinese women: large study in Jiexiu, Shanxi Province, China.

Authors:  Zhilian Wang; Jintao Wang; Jinrong Fan; Weihong Zhao; Xin Yang; Lingmei Wu; Dongyan Li; Ling Ding; Wei Wang; Junjie Xu; Michelle Stram; Chengquan Zhao; Min Hao
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

5.  Diagnostic Yield and Performance of a Large Population-Based Cervical Cancer Screening Program in High-Risk Rural China.

Authors:  Zhilian Wang; Tiannan Wang; Jing Yang; Wei Wang; Lili Zhang; Xiaoqiang Su; Zhe Wang; Haitao Zhang; Jinghui Song; Weiguo Lv; Jintao Wang; Chen Wang; Chengquan Zhao; Min Hao
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

6.  HPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China.

Authors:  Baowen Zheng; Huaitao Yang; Zaibo Li; Guijian Wei; Jia You; Xiaoman Liang; Chengquan Zhao
Journal:  J Cancer       Date:  2017-07-23       Impact factor: 4.207

7.  Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.

Authors:  Dongman Zhao; Liran Zhang; Fengxiang Xie; Dezhi Peng; Jie Wei; Lingbo Jiang; Shoudu Zhang; Debo Qi
Journal:  BMC Cancer       Date:  2020-08-26       Impact factor: 4.430

8.  International telepathology consultation: Three years of experience between the University of Pittsburgh Medical Center and KingMed Diagnostics in China.

Authors:  Chengquan Zhao; Tao Wu; Xiangdong Ding; Anil V Parwani; Hualin Chen; Jeffrey McHugh; Anthony Piccoli; Qinling Xie; Gonzalo Romero Lauro; Xiaodong Feng; Douglas J Hartman; Raja R Seethala; Shangwei Wu; Samuel Yousem; Yaoming Liang; Liron Pantanowitz
Journal:  J Pathol Inform       Date:  2015-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.